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Abstract
Background: Human immunodeficiency virus type-1 (HIV-1) and opiates cause long-term inflammatory insult to
the central nervous system (CNS) and worsen disease progression and HIV-1-related neuropathology. The
combination of these proinflammatory factors reflects a devastating problem as opioids have high abuse liability
and continue to be prescribed for certain patients experiencing HIV-1-related pain.
Methods: Here, we examined the impact of chronic (3-month) HIV-1 transactivator of transcription (Tat)
exposure to short-term (8-day), escalating morphine in HIV-1 Tat transgenic mice that express the HIV-1 Tat
protein in a GFAP promoter-regulated, doxycycline (DOX)-inducible manner. In addition to assessing morphine-
induced tolerance in nociceptive responses organized at spinal (i.e., tail-flick) and supraspinal (i.e., hot-plate)
levels, we evaluated neuroinflammation via positron emission tomography (PET) imaging using the [18F]-PBR111 ligand,
immunohistochemistry, and cytokine analyses. Further, we examined endocannabinoid (eCB) levels, related non-eCB
lipids, and amino acids via mass spectrometry.
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Results: Tat-expressing [Tat(+)] transgenic mice displayed antinociceptive tolerance in the tail withdrawal and hot-
plate assays compared to control mice lacking Tat [Tat(−)]. This tolerance was accompanied by morphine-dependent
increases in Iba-1 ± 3-nitrotryosine immunoreactive microglia, and alterations in pro- and anti-inflammatory cytokines,
and chemokines in the spinal cord and striatum, while increases in neuroinflammation were absent by PET imaging of
[18F]-PBR111 uptake. Tat and morphine exposure differentially affected eCB levels, non-eCB lipids, and specific amino
acids in a region-dependent manner. In the striatum, non-eCB lipids were significantly increased by short-term,
escalating morphine exposure, including peroxisome proliferator activator receptor alpha (PPAR-α) ligands N-oleoyl
ethanolamide (OEA) and N-palmitoyl ethanolamide (PEA), as well as the amino acids phenylalanine and proline. In the
spinal cord, Tat exposure increased amino acids leucine and valine, while morphine decreased levels of tyrosine and
valine but did not affect eCBs or non-eCB lipids.
Conclusion: Overall results demonstrate that 3 months of Tat exposure increased morphine tolerance and potentially
innate immune tolerance evidenced by reductions in specific cytokines (e.g., IL-1α, IL-12p40) and microglial reactivity. In
contrast, short-term, escalating morphine exposure acted as a secondary stressor revealing an allostatic shift in CNS
baseline inflammatory responsiveness from sustained Tat exposure.
Keywords: Opioid drug abuse, [18F]-PBR111 PET imaging, Endocannabinoids, Peroxisome proliferator activator receptor
α (PPAR-α) agonists, Microgliosis, Cytokines, Chemokines, Anti-inflammation, Proinflammation, Phenylalanine, Aliphatic
side-chain amino acids
Background
Studies investigating the effects of opiate abuse, includ-
ing prescription drugs, in human immunodeficiency
virus type-1 (HIV-1)–infected patients demonstrate mul-
tiple comorbid interactions of opiates on the HIV-1-
infected nervous system. Opiates promote HIV-1-related
disease progression [1–4], HIV-1-associated neuropathy
[5–8], and HIV-1 encephalopathy, especially prior to the
introduction of combined antiretroviral therapy (pre-
cART) [9–14]. The deleterious effects of opiates on neu-
roHIV in the central nervous system (CNS) include in-
creased inflammatory products within infected glia that
contribute to bystander dysfunction and toxicity in unin-
fected neurons and glia (for detailed reviews, please see
[7, 13, 15, 16]). Since the inception of cART, the impact
of chronic inflammatory insult by HIV-1 infection has
become an important topic; persistent latently and pro-
ductively infected perivascular macrophage and micro-
glial populations [14, 17–19] represent the primary
reservoirs for HIV-1 in the CNS [20–24]. In vivo and
in vitro studies focusing on the HIV-1 transactivator of
transcription (Tat) protein demonstrate morphine’s ex-
acerbating effects on microglial activation [25–29], astro-
glia dysregulation [29–32], cytokine production [33–38],
and blood-brain barrier (BBB) breakdown [13, 39, 40],
with additional effects on oxidative stress [33, 34, 41,
42], intracellular calcium [34, 37, 43], and neurotoxicity
[38, 42–44], potentially due to morphine’s action on μ-
opioid receptor (MOR)-expressing glia [31, 45]. Notably,
HIV-1 and HIV-1 proteins, such as Tat, impact opioid
gene expression and splicing specificity [38, 46–48], po-
tentially mediated through the release of various proin-
flammatory cytokines, including IL-6, TNF, GM-CSF,
and IFN-γ [49, 50]. Further, the proinflammatory effects
of HIV-1 Tat at C-C chemokine receptor type 5 (CCR5)
desensitize MOR or δ-opioid receptors (DOR [51–53]),
an effect that appears to contribute to decreased antino-
ciceptive potency of morphine in Tat transgenic mice
[54]. Interestingly, recent research has demonstrated
long-term immune tolerance to repeated inflammatory
insult within resident microglia in the CNS, which could
impact the response to morphine after chronic Tat ex-
posure [55–58].
Additionally, changes in various small molecules, such
as endocannabinoids (eCBs) as well as non-eCB lipid
signaling molecules and amino acids have been impli-
cated in opioid-induced antinociception, tolerance, and
dependence [59–66]. Morphine exposure leads to upreg-
ulated cannabinoid receptor type 1 (CB1R) expression
[62, 67, 68], while CB1R knockout mice display markedly
reduced reinforcing/rewarding responses to morphine or
heroin, and inhibitors of eCB degradative enzymes re-
duce opioid withdrawal as well as opioid-seeking behav-
ior in mice [61, 62, 64]. Morphine-tolerant rodents show
complex changes in eCB levels and/or related non-
eCB lipid signaling molecules (e.g., N-oleoyl ethanola-
mide; OEA and N-palmitoyl ethanolamide; PEA), with
reports ranging from upregulation to downregulation
depending on the brain region, duration of exposure,
and the particular eCB(s) or lipid(s) assessed [69–72].
Similarly, the levels of specific amino acids have been
demonstrated to be altered in the brains of rodents ex-
posed to opioids [59, 60]. When given as dietary sup-
plements, tyrosine, L-glutamine, and L-5-
hydroxytryptophan allay some of the physical and emo-
tional aspects of opioid withdrawal, presumably by
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restoring neurotransmitter levels to normative values [73].
Some amino acids (e.g., proline and phenylalanine) are
known for their anti-inflammatory and analgesic proper-
ties [74, 75], although high plasma concentrations of
branched-chain amino acids (BCAA) above 2 mmol/L can
contribute to proinflammatory effects and oxidative stress
[76]. Further, eCBs and related non-eCB lipids possess
neuroprotective, anti-inflammatory, and neurotrophic
properties that likely play a role in various neurodegenera-
tive diseases, including Parkinson’s and Alzheimer’s dis-
ease models [77–81]. However, the interactive effects of
chronic HIV-1 Tat and morphine exposure on patho-
physiological changes in eCBs and related non-eCB lipids
have not been investigated in detail.
In the present study, we assessed morphine tolerance
in the spinal cord-mediated tail-flick task and a suprasp-
inal hot-plate assay in the Tat transgenic mouse model
with chronic induction of Tat expression for 3 months
and administration of a short-term 8-day escalating mor-
phine regimen. To examine neuroinflammation, positron
emission tomography (PET) imaging experiments were
conducted using the 2-(6-chloro-2-(4-(3-18F-fluoropro-
poxy)phenyl)imidazo[1,2-a]pyri-din-3-yl)-N,N-diethylace-
tamide ([18F]-PRB111) imaging probe that specifically
binds to the peripheral benzodiazepine receptor (PBR), re-
cently named as the 18-kDa translocator protein (TSPO).
[18F]-PRB111 is a second-generation PET ligand for TSPO
and a promising imaging agent for TSPO expression in
neurodegenerative disorders [82–84]. Additionally, we
identified activated microglia using ionized calcium bind-
ing adaptor molecule 1 (Iba-1) and 3-nitrotyrosine (3-NT)
immunoreactivity, and measured cytokines by multiplex
immunoassay in the striatum and spinal cord of Tat trans-
genic mice. To determine the impact of HIV-1 Tat and
opioid exposure on the eCB system in these two CNS re-
gions, we examined 2-arachidonoyl glycerol (2-AG), N-
arachidonoyl ethanolamide (AEA), and related non-eCB
lipids in Tat transgenic mice via mass spectrometry.
Lastly, mass spectrometry analyses assessed alterations in
the concentration of multiple amino acids in the spinal
cord and striatum of Tat transgenic mice. We hypothe-
sized that HIV-1 Tat expression attenuates morphine-
induced antinociceptive tolerance after morphine expos-
ure, potentially due to alterations of inflammatory pro-
cesses and changes in expression levels of eCBs,
related non-eCB lipids, and amino acids.
Materials and methods
Animals
Doxycycline (DOX)-inducible, brain-specific HIV-1IIIB
Tat1-86 transgenic mice (~ 3 months of age, ~ 25 g,
males) were used in the present study and developed on
a C57BL/6J hybrid background as previously described
[29, 85]. To induce Tat expression in mice that express
the GFAP-rtTA and TRE-tat genes [Tat(+) mice], ani-
mals were fed a specially formulated chow containing
6 mg/g DOX (Harlan, Indianapolis, IN, product #:
TD.09282). Control Tat(−) transgenic mice that ex-
press only the GFAP-rtTA gene and lack the tat
transgene received the same DOX diet. Mice were fed
the DOX-supplemented food for up to 3 months be-
fore experiments were conducted. Mice had free ac-
cess to water and chow and were group-housed (2–4
mice per cage) on a reversed 12 h light/dark cycle
(lights off at 8:00 AM). All animal procedures were
approved by the University of North Carolina at
Chapel Hill (UNC) Institutional Animal Care and Use
Committee (IACUC) and were in keeping with ethical
guidelines defined by the National Institutes of Health
(NIH Publication No. 85-23).
Repeated Escalating Morphine Injections
Morphine sulfate was obtained from the National Institutes
of Health National Institute on Drug Abuse (Drug Supply
System, Bethesda, MD) and dissolved in 0.9% physiological
saline. Saline and morphine were administered via the
subcutaneous (s.c.) route in an injection volume of 10 mL/
kg. To induce tolerance, morphine was administered in es-
calating doses via twice daily injections for 8 days (8:00 AM
and 6:00 PM): 10 mg/kg on day 1, 20 mg/kg on days 2 and
3, 40 mg/kg on days 4 and 5, 80 mg/kg on day 6, and 160
mg/kg on days 7 and 8, based on previous studies using
similar escalating injection regimens [86, 87]. Saline-treated
animals received an equivalent volume of sterile, 0.9%
physiological saline.
Behavioral tolerance studies
Acute cumulative morphine injections
To assess opioid tolerance, acute cumulative morphine
dose-response curves were evaluated in mice that re-
ceived the 8-day escalating morphine dosing regimen or
eight days of saline injections. On test day (i.e., day 9 at
8:00 AM), the saline-injected group received cumulative
s.c. morphine doses of 2, 4, 8, and 16 mg/kg, whereas
the morphine-exposed group received cumulative mor-
phine doses of 8, 16, 32, and 64 mg/kg (Fig. 1). Mice
were tested before and immediately after each acute cu-
mulative s.c. morphine injection. The tail-flick and hot-
plate assays were used to test for tolerance to morphine’s
antinociceptive effects. Baseline responses for tail-flick
and hot-plate activity were measured on test day 9 be-
fore animals received acute cumulative s.c. morphine in-
jections. Following a 20-min absorption period after
each injection, tail-flick responses were recorded
followed by hot-plate responses. After the last injection,
mice were sacrificed and the brains were harvested and
processed for immunohistochemistry, cytokine analysis,
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eCB and related non-eCB lipid analysis, and amino acid
analysis.
Tail-flick and hot-plate tests
The tail-flick test was conducted on Tat transgenic mice
(n = 7–9 per group) using a water bath with the
temperature maintained at 56 ± 0.1 °C. For baseline la-
tency, tail withdrawal was measured on day 9 before acute
cumulative morphine injections. The distal 1/3 of the
mouse-tail was immersed in the warm-water bath and the
latency for the mouse to remove its tail was measured.
The duration of time the tail remained in the water bath
was counted as the baseline latency. Baseline latency reac-
tion times in mice before acute cumulative morphine in-
jections were 2 to 3 s. Test latency was evaluated 20 min
after each cumulative morphine injection with the latency
to remove the tail increasing proportionally to morphine’s
analgesic potency. A 10-s maximum cut-off latency was
used to prevent tissue damage.
Immediately after the tail-flick test, a subset of animals
(n = 3–4 per group) were evaluated in the hot-plate test
of nociception. Subjects were gently placed on the sur-
face of the hot plate (55 ± 0.1 °C; IITC, Inc., MOD 39).
Round Plexiglas™ walls (15 cm high, 10 cm diameter)
surrounded the hot plate to prevent escape. Latency to
lick or lift a hindpaw was the dependent measure. Hot-
plate baselines were taken before acute cumulative mor-
phine injections and after tail-flick assessment with base-
line latency reaction times ranging from 4 to 8 s. Test
latency was obtained after each cumulative morphine in-
jection following the tail-flick assessment. A 20-s max-
imum cut-off latency was used to prevent tissue damage.
Antinociception in the tail-flick and hot-plate assays
were quantified as the percentage of maximum possible
effect (%MPE), which was calculated as %MPE = [(test
latency − control latency) / (maximum cut-off latency −
control latency)−1] × 100 [88].
Positron emission tomography analysis
All animal positron emission tomography (PET) and
computed tomography (CT) imaging were conducted in
the Small Animal Imaging Facility of the Biomedical Re-
search Imaging Center (BRIC) at UNC.
The synthesis of [18F]-PBR111 was performed as previ-
ously described [89–91]. The [18F]-PBR111 probe was
produced at the BRIC Cyclotron and Radiochemistry Core
facility according to the well-established radiosynthesis
method [83, 84]. Radiochemical purity was > 95% and the
specific activity was 219.78 ± 35.89 GBq/μmol.
PET/CT image acquisition was performed using a
small animal PET/CT scanner (Argus, Sedecal, Inc.
Spain) with a spatial resolution of 1.2 mm in the center
field of view. Tat transgenic mice (n = 5–7 per group)
were anesthetized with inhalation of 1.5–2.5%
isoflurane-oxygen gas mixture. The tail vein was cathe-
terized for radiotracer injection. A dose of [18F]-PBR111
(~ 11 MBq in 100 μL) was administered through the
mouse tail vein. At 40-min post injection, a 20-min PET
acquisition was conducted after a CT scan. PET images
were reconstructed using the 2D-OSEM algorithms with
scatter, attenuation, and decay correction. Standardized
uptake value (SUV) was calculated voxel wise by normal-
izing the signal to the injection dose and animal body
mass. After PET/CT images, brains were collected and
the distribution of [18F]-PBR111 binding within the brain
in higher resolution was assessed using autoradiography
following standard procedures. Briefly, brain specimens
were snap-frozen and cryo-sectioned at 12 μm thickness.
The sections were placed on a phosphor screen for over-
night exposure, and autoradiography images were
Fig. 1 Experimental design depicted on a timeline. All Tat transgenic mice received DOX-containing chow for 3 months and were then
subcutaneously (s.c.) injected with saline or morphine for 8 days, except for a separate set of mice that were PET imaged as control animals (no
injections), which received DOX for 2 weeks. Body mass was recorded daily. On day 9 after morphine administration, mice were tested for
baseline activity in the tail-flick and hot-plate assays. This was followed by four acute, cumulative s.c. morphine injections with a 20-min wait
period after each injection before tail-flick responses to warm-water and hindpaw lick or lift to a heated hot-plate were tested. At the end of
behavioral testing, animals were sacrificed immediately and brains were taken for immunohistochemistry and mass spectrometry analysis.
Cytokine analyses were conducted on a separate set of animals. TF tail-flick assay, HP hot-plate assay, PET positron emission tomography, MS mass
spectrometry, Cytokine cytokine analyses; n = mice per group
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obtained after digital scan using a phosphor imaging sys-
tem (Cyclone Plus, PerkinElmer Inc.). Standard T2-
weighted magnetic resonance images were acquired
from eight Tat transgenic mice to form an averaged
magnetic resonance imaging (MRI) atlas and provide the
substructure reference within brains for the PET images.
For PET data analysis, PET images were first registered
to the MRI atlas images via co-registered CT images. Re-
gions of dorsal striatum, hippocampus, frontal cortex,
and cerebellum were first drawn in the MRI images as
the volumes of interest (VOIs) and superimposed to
PET images. Uptake level in each brain VOI was
expressed as SUV. The mean SUV and variation were
calculated for each group.
Immunohistochemistry: microglia (Iba-1+) and activated,
3-nitrotyrosine microglia (3-NT+ Iba-1+)
Half of the Tat transgenic mice (n = 3–4 per group)
were anesthetized with isoflurane and perfused with 4%
paraformaldehyde. Brains and the spinal cord (including
C1 to C5 as well as the lumbar region from L1 to L5)
were removed and post-fixed in 4% paraformaldehyde
(for 6 h at 4 °C), then washed in 1× phosphate-buffered
saline (PBS) several times and incubated for at least 32 h
in 20% sucrose in PBS. Brains were embedded in Tissue-
Tek O.C.T. compound, frozen, and stored at − 80 °C
until cut. Sagittal brain sections (30 μm) containing the
frontal cortex, hippocampus, dorsal striatum, and cere-
bellum, and coronal spinal cord sections (30 μm, por-
tions of the C1–C5, and L1–L5) were cut on a Leica
CM3050S cryostat (Leica, Deerfield, IL). Sections were
first incubated in 0.5% H2O2 for 30 min, in 1% H2O2 for
60 min, and again in 0.5% H2O2 for 30 min, incubated
for 30 min in permeability solution (PBS with 0.2% Tri-
ton X-100 and 1% bovine serum albumin; performed for
3-NT staining only), followed by exposure to blocking
buffer for 1 h (PBS with 3% normal goat serum and 0.5%
Triton X-100 for Iba1 staining, or 1% normal goat serum
and 4% bovine serum albumin for 3-NT staining). Sec-
tions were then incubated with the primary antibodies
against Iba-1 (rabbit, Wako, #019-19741; 1:500) for the
detection of microglia and/or 3-NT (mouse, Santa Cruz,
#SC-32757; 1:100), a reactive nitrosyl product formed by
reactive nitrogen species such as peroxynitrite, diluted in
blocking buffer containing normal goat serum, overnight
at 4 °C. The primary antibodies were detected using
goat-anti-rabbit Alexa 488 (ThermoFisher, #A-11034, 1:
500) and/or goat-anti-mouse Alexa 594 (ThermoFisher,
#A-11032, 1:500). The secondary antibody was diluted in
goat blocking buffer and applied to the sections for 1 h
at room temperature. Cell nuclei were visualized with
Hoechst 33342 (Molecular Probes, H3570, exposed for 3
min). Tissue sections were washed thoroughly with PBS
and coverslipped with antifade mounting medium
(VectaShield, #H-1400). Confocal immunofluorescent
images were acquired using a Zeiss LSM T-PMT laser
scanning confocal microscope (Zeiss, Thornwood, NY)
equipped with a × 20 objective. Images were collected
using ZEN 2010 Blue Edition software (Carl Zeiss, Inc.,
Thornwood, NY). For the frontal cortex, hippocampus,
striatum, and cerebellum, one image was sampled per
section from ≥ 4 sagittal sections, spaced 300 μm apart,
per animal. For the coronal spinal cord sections, one
image was sampled per section from ≥ 4 sections spaced
300 μm apart per animal.
Iba-1+ microglial cell bodies containing Hoechst-
stained nuclei were counted by two experimenters
blinded to genotype and morphine/saline injections. Re-
liability (Cronbach’s α) of Iba-1+ counts between the
two experimenters was assessed for each brain region
and the spinal cord ranging between 0.862 and to 0.913
(frontal cortex: α = 0.913, hippocampus: α = 0.875, stri-
atum: α = 0.862, cerebellum: α = 0.891, spinal cord: α =
0.895). Data presented as the number of Iba-1+ micro-
glia represent the average counts from both
experimenters.
Similarly, 3NT+ Iba1+ double-labeled microglia con-
taining Hoechst-stained nuclei were counted by two ex-
perimenters blinded to genotype and morphine/saline
injections. Reliability (Cronbach’s α) of 3NT+ Iba-1+
microglial counts between the two experimenters was
assessed for the striatum (α = 0.809) and the spinal cord
(α = 0.826). The 3-NT+ Iba1+ microglial counts repre-
sent the average of both experimenters.
Additionally, Sholl analysis of microglia morphology
was performed following previous published studies [92,
93]. Briefly, confocal microscopy was used to collect x
63 z-stack images of the striatum and spinal cord (n =
3–4 mice per group/4 sections each) immunodetected
for Iba-1 and stained with Hoechst (as outlined above).
Maximal intensity projections images were prepared
using ZEN 2010 Blue Edition software (Carl Zeiss, Inc.,
Thornwood, NY) and exported to Fiji build of ImageJ. A
total of 4 microglia per animal were individually isolated
for analysis per random selection [93]. The soma size
was measured in Fiji and the line segment tool was used
to draw a line from the center of each soma to the tip of
its longest process, providing the maximum branch
length (μm). The Sholl analysis plugin software was used
to assess additional measures, with the first shell set at
10 μm and subsequent shells set at 5 μm sizes, to deter-
mine intersections at each Sholl radius. This provided
the critical radius (radius value with the highest number
of intersections), the process maximum (the highest
number of intersections regardless of radius value), the
number of primary processes (intersections at the first
Sholl radius), and the process total (total number of
intersections).
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Cytokine analysis
Cytokine protein levels were detected in the dorsal stri-
atum and spinal cord by multiplex immunoassay (Mouse
Cytokine 23-plex assay kit; #M60009RDPD; Bio-Rad La-
boratories, Inc., Hercules, CA, USA) and measured using
Bio-Plex 200 plate-reader (Bio-Rad) (Tables 3 and 4). In
brief, separate groups of control or Tat transgenic mice
(n = 5–6 per group) were treated with morphine and/or
DOX, samples were dissected, frozen on dry ice, and ho-
mogenized in immunoprecipitation (IP) lysis buffer
(#87787; Pierce Biotechnology, Rockford, IL, USA) con-
taining an EDTA-free protease/phosphatase inhibitor
cocktail (#04693159001; Roche, Mannheim, Germany).
Following a bicinchoninic acid assay (#23224; Pierce Bio-
technology), protein levels were normalized to 900 μg/
mL (striatum) or 500 μg/mL (spinal cord) and run in du-
plicate on the Bio-Plex assay as per manufacturer’s in-
structions. Cytokine concentrations were calculated
from concurrent standard curves on a five-parameter lo-
gistic curve within Bio-Plex Manager 4.0 software.
Analysis of endocannabinoids and other lipids
Endogenous cannabinoid ligands, including the two
main endocannabinoids (eCBs) AEA and 2-AG as well
as nine related lipids, including N-arachidonoyl glycine
(NAGly), peroxisome proliferator activator receptor
(PPAR) ligands, such as OEA and PEA, and 2-linoleoyl
glycerol (2-LG) were quantified in the dorsal striatum
and spinal cord in half of the Tat transgenic mice (n =
3–5 per group) after behavioral testing via mass spec-
trometry (Table 5). Brains were removed immediately
following cervical dislocation and decapitation, then the
striatum and spinal cord were rapidly dissected, frozen
in liquid nitrogen, and stored at − 70 °C until use, as pre-
viously described [94]. Samples from the right hemi-
sphere were processed, and substrates were quantified in
a manner similar to previous studies [95]. Briefly, frozen
striatum and spinal cord samples stored in microfuge
tubes were removed from the − 70 °C freezer and imme-
diately placed on dry ice. Each entire sample was then
weighed in a TissueLyzer tube with stainless steel ball
(QIAGEN, Hilden, Germany), the weight was recorded,
and the samples were placed on dry ice until
homogenization. Immediately before homogenization,
440 μL of ice-cold methanol (Fisher Scientific, Fair
Lawn, NJ), 50 μL of internal standard containing 50 ng/
mL 2-AG-d5, 5 ng/mL of AEA-d4, 5 ng/mL of OEA-d4
(Cayman Chemical, Ann Arbor, MI), and 10 μL of 5 mg/
mL BHT (Sigma Aldrich, St. Louis, MO) in methanol
antioxidant solution was added. Samples were then ho-
mogenized at 50 Hz for 2 min (QIAGEN TissueLyzer
LT). Immediately after homogenization, samples were
placed in a microcentrifuge at 14,000 RPM for 10 min at
4 °C. The supernatant was removed and placed in an
MRQ reduced surface activity vial (Microsolv, Leland,
NC) and analyzed immediately by liquid chromatog-
raphy coupled with tandem mass spectrometry [LC/MS/
MS; 95]. Immediately after analysis, the remaining
supernatant was placed into a − 70 °C freezer and stored
until amino acid analysis was performed.
Amino acid analysis
Various amino acids, including arginine, aspartic acid, glu-
tamic acid, glycine, leucine, phenylalanine, proline, serine,
tyrosine, and valine, were quantified from the remaining
supernatant of the dorsal striatum and spinal cord after
eCB analysis (Table 6). Samples (n = 3–5 per group) were
processed and substrates quantified as follows; briefly, 10
μL of the striatum or spinal cord homogenate superna-
tants obtained in the “Analysis of endocannabinoids and
other lipids” section were combined with 10 μL of PBS
and 10 μL of amino acid internal standard NSK-A (Cam-
bridge Isotope Laboratories, Tewksbury, MA) in 1.5 mL
microcentrifuge tubes and placed in a vacuum centrifuge
at 55 °C until dry. Samples were then reconstituted with
100 μL of 0.05 N hydrochloric acid and transferred to an
MRQ reduced surface activity vial. Amino acids were then
analyzed by HILIC-LC/MS/MS as previously described
[96] with modifications. Briefly, 1 μL of each sample was
injected on an Agilent 2.1 mm × 150 mm, 2.7 μm HILIC-
Z column on an Agilent 1260 series high-performance li-
quid chromatography (HPLC) coupled with an Agilent
6490 triple quadrupole mass spectrometer (Agilent Tech-
nologies, Santa Clara, CA). Buffer A consisted of 20 mM
ammonium formate in water (pH = 3) and buffer B con-
sisted of 9:1 acetonitrile:water with 20 mM ammonium
formate (pH = 3). The HPLC was run with a linear gradi-
ent from 0 to 30% buffer A over 10 min at a flow rate of
0.8 mL/min. Mass spectrometric analysis was performed
in positive ionization mode. The drying gas was 290 °C at
a flow rate of 11 mL/min. The sheath gas was 390 °C at 11
mL/min. The nebulizer pressure was 35 psi. The capillary
voltage was 3500 V. Data for amino acids was acquired in
dynamic MRM mode using experimentally optimized col-
lision energies obtained by flow injection analysis of au-
thentic standards. Calibration standards for each amino
acid were analyzed over a range of concentrations from
0.16 to 100 μM. Calibration curves for each amino acid
were constructed using Agilent Masshunter Quantitative
Analysis software. Striatum and spinal cord samples were
quantitated using the calibration curves to obtain the on-
column concentration, followed by multiplication of the
results by the appropriate dilution factor to obtain the
concentration in pmol/mg of tissue.
Experimental design
The experimental design is depicted on a timeline in Fig.
1. Tat transgenic mice were exposed to 3 months of
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DOX treatment to chronically induce Tat expression,
which was followed by repeated injections of saline or
morphine for 8 days. Body mass was recorded daily.
Tat(−) and Tat(+) mice exposed to the escalating
morphine doses were imaged on day 8 after morning
injections. PET imaging for the control groups was
conducted on a different set of Tat(−) and Tat(+) ani-
mals that did not receive any injections and were ex-
posed to DOX for 2 weeks. For the behavioral
tolerance experiments, antinociceptive tail-flick and
hot-plate assays were conducted in the morning of
day 9. Brains were harvested immediately after behav-
ioral testing for immunohistochemistry and mass
spectrometry analyses. Cytokine analyses were con-
ducted on a separate set of animals.
Statistical analysis
All data are presented as mean ± the standard error of
the mean (SEM). Data sets from body mass, behavioral
assays, immunohistochemistry, PET imaging, cytokine
assays, and mass spectrometry were analyzed by analysis
of variance (ANOVA) with genotype [2 levels: Tat(−)
mice, Tat(+) mice] and drug (2 levels: saline, morphine)
as between-subjects factors and time or CNS region as a
within-subjects factor when appropriate. Violations of
compound symmetry in repeated-measures ANOVAs
for the within-subjects factors (i.e., comparing time
points) were addressed by using the Greenhouse-Geisser
degrees (pGG) of freedom correction factor [97]. ANO-
VAs were followed by Tukey’s post hoc tests when ap-
propriate (SPSS Statistics 25; IBM, Chicago, IL; and/or
GraphPad 8.0, San Diego, CA). Thus, differences of α <
0.05 were considered statistically significant. In the tail-
flick and hot-plate assays, the dose-response data for
%MPE were additionally analyzed for ED50 and potency
ratios. ED50 values were calculated using sigmoidal
curvilinear analysis with a variable slope model fixing
bottom and top value constraints of 0 and 100, respect-
ively (Prism 8 for Mac OS X; GraphPad Software, La
Jolla, CA). The ED50 values were considered significantly
different if the upper and lower 95% confidence interval
(CI) between the dose-response curves did not overlap.
Potency ratio values (specifically, ED50 shifts) were cal-
culated for parallel curves with fixing bottom and top
value constraints of 0 and 100, respectively. A potency-
ratio value of greater than 1.0 with a lower 95% CI > 1.0
was considered a significant difference in potency be-
tween two dose-response curves (saline versus morphine
groups). It should be noted that for the tail-flick assay,
values for the short-term morphine-exposed Tat(+) mice
did not exceed 50%, thus we are using an estimated
ED50 value for this group that might not reflect the true
ED50 value.
Results
Body mass and morphine-induced antinociceptive
tolerance
Body mass was recorded daily throughout the 8-day re-
peated injection regimen (Fig. 2a). A three-way mixed
ANOVA with time as a within-subjects factor (using
Greenhouse-Geisser degrees (pGG) of freedom as a cor-
rection factor [97]) and genotype and drug as between-
subjects factors was conducted. A significant main effect
of time [F(7, 196) = 65.6, pGG < 0.001] and time × drug
interaction [F(7, 196) = 34.0, pGG < 0.001] were noted,
with a significant reduction in body mass over injection
days for morphine-treated groups [Tat(−) mice, F(7, 42)
= 35.0, pGG < 0.001; Tat(+) mice, F(7, 56) = 48.1, pGG
< 0.001], but not saline-exposed Tat(−) and Tat(+)
groups. This morphine-induced decline in body mass
was confirmed statistically by an overall main effect of
drug [F(1, 28) = 10.8, p = 0.003]. Further, a significant
main effect of genotype was noted [F(1, 28) = 15.8, p <
0.001], with Tat(+) mice demonstrating lower body mass
compared to Tat(−) mice independent of drug exposure.
The antinociceptive effects of morphine were deter-
mined using the tail-flick and hot-plate assays (Fig. 2b,
c). All groups, except the Tat(−) group in the hot-plate
test, demonstrated tolerance following the 8-day re-
peated escalating morphine dosing regimen compared to
saline-treated mice in both assays (Table 1). The re-
peated morphine dosing regimen led to rightward shifts
in the acute morphine dose-response curves in Tat(−)
and Tat(+) mice compared to saline exposure, as indi-
cated by significant differences in the ED50 values (based
on non-overlapping 95% CI) with potency ratio values
varying between 3.2- and 6.7-fold (Table 1). Note that
potency ratios for the hot-plate test did not reveal sig-
nificance in Tat(−) and Tat(+) mice, potentially due to
the small sample size that increased the likelihood of
type II error. Additional ANOVA results further support
the notion of induced tolerance by morphine with sig-
nificant decreased %MPE in the tail-flick assay for re-
peated morphine-exposed mice compared to mice
receiving saline after acute cumulative morphine injec-
tions of 8 mg/kg [Tat(−), F(1, 13) = 11.6, p = 0.005,
Tat(+), F(1, 15) = 14.9, p = 0.002] and 16 mg/kg [Tat(−),
F(1, 13) = 18.7, p = 0.001, Tat(+), F(1, 15) = 27.9, p <
0.001; Fig. 2b]. Similar effects were noted for the hot-
plate assay, with ANOVA results demonstrating signifi-
cant decreased %MPE values in repeated morphine-
exposed mice after the 8 mg/kg acute cumulative mor-
phine dose injection compared to mice receiving saline
[Tat(+), F(1, 6) = 5.8, p = 0.052] and 16 mg/kg [Tat(−),
F(1, 5) = 11.9, p = 0.018, Tat(+), F(1, 6) = 22.1, p =
0.003; Fig. 2c]. Importantly, an increased tolerance is
noted by Tat induction in the tail-flick assay with the es-
timated ED50 value for morphine-treated Tat(+) mice
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significantly differing from the ED50 value for the
morphine-exposed Tat(−) mice (based on non-
overlapping 95% CI, see Table 1). Further, when exposed
to repeated escalating morphine, Tat(+) mice displayed
decreased tail-flick %MPE (44.9 ± 6.7) compared to
Tat(−) mice (79.5 ± 9.7) in response to an acute injec-
tion of 64 mg/kg morphine (tail flick, F(1, 14) = 9.2, †p =
0.009, Fig. 2b), supporting the notion that Tat increased
the tolerance to repeated morphine exposure. No other
significant effects were noted. Together, these results
support previous tail flick data showing that Tat expres-
sion increases morphine tolerance for the tail-flick task
Fig. 2 Body mass and behavioral tolerance in Tat transgenic mice
were significantly impacted by Tat exposure and morphine
treatment. a Time course of body mass in Tat(−) and Tat(+) mice
exposed to repeated injections of saline or morphine for 8 days.
Morphine significantly decreased body mass for Tat(−) and Tat(+)
groups overall and across time. Further, Tat expression decreased
body mass for Tat(+) mice compared to Tat(−) mice. All data are
expressed as mean ± SEM. Statistical significance was assessed by
ANOVAs followed by Tukey’s post hoc tests; *p = 0.003 main effect
of drug; §p < 0.001 time × drug interaction; #p < 0.001 main effect
of genotype. Morph short-term (8-day) morphine injections. n = 7–9
mice per group. b, c Assessment of morphine-induced
antinociceptive tolerance in Tat(+) mice compared to Tat(−) mice
after morphine or saline exposure for eight days. Each data point
represents the mean of the percent maximum possible effect of tail
withdrawal (tail flick) or paw withdrawal/lick (hot plate) relative to
baseline as a function of acute morphine dose (mg/kg). b For the
tail-flick assay repeated morphine exposure produced tolerance in
Tat(−) and Tat(+) mice compared to their saline-exposed
counterparts as indicated by the significant 3.2-fold and 6.7-fold
increases in the potency ratios, respectively (ap < 0.05). Importantly,
the 6.7-fold increase in potency for Tat(+) mice was significantly
higher than the 3.2-fold increase for Tat(−) mice (based on non-
overlapping 95% confidence interval, §p < 0.05, see Table 1 for
details), indicating increased tolerance for Tat(+) compared to Tat(−)
mice when repeatedly exposed to morphine. Note, as the potency
ratio of 6.7 is based on an estimated ED50 value, caution should be
exercised when interpreting the data. Nevertheless, the significant
difference between Tat(−) and Tat(+) mice is supported by ANOVA
results, specifically in response to an acute morphine injection of 64
mg/kg (†p = 0.009). c For the hot-plate assay morphine-induced
tolerance was less robust. ANOVA results indicated significance at 8
mg/kg and/or 16 mg/kg as well as significant differences in ED50
values for Tat(+) mice exposed to saline versus morphine (based on
non-overlapping 95% confidence interval, see Table 1 for details).
However, the 2.7- and 4.4-fold increase in potency ratio for
morphine exposure in Tat(−) and Tat(+) mice, respectively, was not
significant. All data are expressed as mean ± SEM. Statistical
significance was assessed by ANOVA followed by Tukey’s post hoc
test; *p < 0.05 vs. 8 or 16 mg/kg acute morphine administration in
the corresponding Tat mouse group exposed to repeated morphine;
for Tat(+) mice: #p < 0.05 vs. Tat(+) mice exposed to repeated
morphine. “PR” = potency ratio, as determined by the ED50 shift
between the saline and morphine-exposed groups (see text for
details), ap < 0.05; §p < 0.05 vs. 3.2-fold PR for Tat(−) mice. Morph
short-term (8-day) morphine injections, MPE maximun possible
effect, PR potency ratio. Tail flick, n = 7–9 mice per group; hot plate,
n = 3–4 mice per group
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[98] with less robust changes in the supraspinal-related
hot-plate assay.
PET [18F]-PBR111 neuroinflammation ligand
Non-invasive PET imaging using the [18F]-PRB111 probe
was conducted to monitor active TSPO inflammatory
processes in the brains of Tat transgenic mice in vivo (n =
5–7 per group; Fig. 3). Uptake of the [18F]-PBR111 radio-
tracer was measured in different brain regions, including
the frontal cortex, hippocampus, striatum, and cerebellum
for the following groups: control Tat(−) mice and Tat(+)
mice, and Tat(−) and Tat(+) mice exposed to morphine
(Fig. 3b). A three-way mixed ANOVA with brain region
as a within-subjects factor and genotype and drug as
between-subjects factors was conducted. Brain region sig-
nificantly affected [18F]-PBR111 uptake [F(3, 60) = 256.4,
pGG < 0.001] with higher levels noted in the cerebellum
compared to any other brain region (p’s < 0.001). No other
effect was significant, indicating that genotype and drug
did not affect brain inflammation assessed by the [18F]-
PRB111 imaging probe, which was confirmed by post-
mortem autoradiography (Fig. 3c).
TPSO is widely expressed by tissues outside the CNS,
including muscle and connective tissue [99, 100] creat-
ing artifactually high [18F]-PRB111 signals in the ventral
forebrain, cerebellum, and spinal cord. The high signal
intensity breaching into the ventral forebrain was mainly
due to the signals outside the brain (Fig. 3a), while in
the cerebellum artificially high signals were caused by
the extensive infolding of meningeal tissue, e.g., the ten-
torium cerebelli. The spinal cord was not examined (i)
because of the strong partial-volume effects resulting
from artifactually increased [18F]-PRB111 signals from
surrounding muscle compared to the small volume of
spinal cord and (ii) because of the limited field of view
of the scanner (47 mm in transaxial length), which is un-
able to image the brain and spinal cord concurrently.
Accordingly, TSPO was not quantified in some ventral
forebrain regions, the cerebellum, or spinal cord. Over-
all, no effects were noted for exposure to Tat and/or
morphine on neuroinflammation assessed by PET im-
aging of [18F]-PBR111 uptake.
Immunohistochemistry
Quantification of number of Iba-1+ microglia in 5 CNS
regions
Immunohistochemistry experiments were conducted to as-
sess microglia by quantifying the number of Iba-1+ immu-
noreactive microglia in various brain regions and the spinal
cord (n = 3–4 per group/4 sections each; Fig. 4a). A three-
way mixed ANOVA with CNS region as a within-subjects
factor and genotype and drug as between-subjects factors
was conducted and revealed significant effects. Number of
microglia differed based on CNS region [F(4, 196) = 129.3,
p < 0.001] with all CNS regions differing from each other
(p’s < 0.001), except for the hippocampus compared to
the striatum. Additionally, morphine increased the number
of microglia [F(1, 49) = 10.0, p = 0.003] and significantly
interacted across CNS regions [F(4, 196) = 2.6, p = 0.040].
To assess this interaction further, separate two-way ANO-
VAs for the four brain regions and spinal cord were con-
ducted and revealed significant effects only for the
striatum and spinal cord. Morphine significantly in-
creased the number of Iba-1+ cells in the striatum
[F(1, 49) = 18.9, p < 0.001] and spinal cord [F(1, 49)
= 4.7, p = 0.036]. Morphine-treated Tat(+) mice
showed increased Iba1+ microglial accumulation com-
pared to saline-treated, Tat(+) mice (striatum, p =
0.002; spinal cord, p = 0.043), and Tat(−) mice (stri-
atum, p < 0.001; spinal cord, p = 0.049; Fig. 4a).
Quantification of activated 3-NT+ Iba-1+ microglia in the
striatum and spinal cord
Immunohistochemistry experiments were conducted
to assess activated microglia by quantifying the num-
ber of 3-NT+ Iba-1+ double-labeled cells in the stri-
atum and spinal cord (n = 3–4 per group/4 sections
each; Fig. 4b). Separate two-way ANOVAs for the
striatum and spinal cord with genotype and drug as
between-subjects factors were conducted and revealed
significant effects for both regions. Morphine
Table 1 Morphine-induced antinociceptive tolerance (%MPE) in the tail-flick (mean ± SEM, n = 7–9 per group) and hot-plate (mean
± SEM, n = 3–4 per group) assays




Sig. Potency ratio (95% CI)
Tail flick Tat(−) 8.6 (7.0–10.5) 26.6 (20.3–34.8) * 3.2 (2.3–4.4)a
Tat(+) 7.8 (6.2–9.8) 91.3 (60.7–137.4)1 * 6.7 (4.6–10.8)a§
Hot plate Tat(−) 6.1 (4.3–8.7) 14.5 (8.1–26.1) n.s. 2.7 (0.5–8.7)
Tat(+) 5.4 (4.2–7.0) 23.0 (11.4–46.3) * 4.4 (0.7–28.9)
ED50 values (mg/kg) and potency ratio values are derived from acute cumulative dose-response curves obtained for repeated short-term saline- and morphine-
exposed mice.; n.s. not significant; *p < 0.05 saline vs. corresponding morphine group; ap < 0.05; §Indicates significance from Tat(−) in the tail-flick assay based on
non-overlapping 95% CI. Note, as the potency ratio of 6.7 is based on an estimated ED50 value caution should be exercised when interpreting the data. CI
confidence interval
1Estimated ED50
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treatment significantly increased the percentage of 3-NT+
Iba-1+ microglia in the striatum [F(1, 55) = 13.9, p < 0.001]
and spinal cord [F(1, 56) = 32.5, p < 0.001], which was also
noted for Tat expression [striatum, F(1, 55) = 7.7, p =
0.008; spinal cord, F(1, 56) = 13.1, p = 0.001]. Morphine
and Tat treatments significantly interacted to increase the
percentage of 3-NT+ Iba-1+ co-localized microglia within
the striatum [F(1, 55) = 9.9, p = 0.003] and a similar trend
was noted for the spinal cord [F(1, 56) = 3.4, p = 0.070].
Specifically, morphine-treated, sections from Tat(+) mice
striatal, and spinal cord showed increased 3-NT+ Iba-1+
microglia compared to sections from Tat(−) mice (stri-
atum, p < 0.001; spinal cord, p = 0.001), as well as com-
pared to sections from saline-treated, Tat(−) mice
striatum (p < 0.001), and spinal cord (p < 0.001), and
Tat(+) mice striatum (p < 0.001) and spinal cord (p <
0.001). Together, these data indicate that increased drug
tolerance was accompanied by morphine-dependent in-
creases in 3-NT+ Iba-1+ immunoreactive microglia.
Sholl analysis of microglia morphology in the striatum and
spinal cord
Sholl analyses were conducted to assess microglia
morphology in the striatum and spinal cord (n = 3–
4 per group/4 sections each; Table 2). Separate two-
way ANOVAs for the striatum and spinal cord with
genotype and drug as between-subjects factors were
conducted and revealed significant effects for only
the spinal cord. Tat treatment significantly enlarged
Fig. 3 No significant changes were noted for neuroinflammation assessed by in vivo PET imaging using the [18F]-PRB111 probe in Tat transgenic mice
in the presence or absence of morphine treatment. a A representative overlay image of a Tat(−) and Tat(+) mice show MR (gray), CT (white), and PET
(SUV scale, yellow-red) imaging in the coronal plane. b PET imaging of Tat transgenic mice demonstrates the successful uptake of the [18F]-PBR111
radiotracer in different brain regions. No significant effect was noted for drug and/or genotype. c A representative brain image of a Tat(−) and Tat(+)
mouse shows similar distribution of [18F]-PBR111 binding via post-mortem autoradiography in both groups in the parasagittal plane approximately 2
mm from the midline. All data are expressed as mean ± SEM. Statistical significance was assessed by ANOVA followed by Tukey’s post hoc test. SUV
standardized uptake value, Crt no injections, Morph short-term (8-day) morphine injections. n = 5–7 mice per group
Hermes et al. Journal of Neuroinflammation          (2020) 17:345 Page 10 of 26
the soma area (Table 2) which is associated with
amoeboid morphology [92]. Additionally, morphine
significantly interacted with Tat in the spinal cord to
decrease number of primary processes (intersections
at the first Sholl radius), process maximum (the
highest number of intersections regardless of radius
value), and process total (total number of intersec-
tions) but Tukey’s post hoc test revealed no signifi-
cant differences between groups for any of the three
measures. Nevertheless, overall morphine exposure
in the presence of Tat expression appears to induce
abnormal morphology specifically in the spinal cord.
Fig. 4 Morphine treatment increased the number of microglia (Iba-1+) and morphine and Tat exposure increased activated microglia (3-NT+ Iba-1+)
in the striatum and spinal cord of Tat transgenic mice. a Quantification of Iba-1+ cell counts in 5 different CNS regions, including the frontal cortex,
hippocampus, striatum, cerebellum, and spinal cord were examined for Iba-1+ cells. Morphine upregulated Iba-1+ cell counts in the striatum and
spinal cord, specifically for the morphine-treated, Tat(+) mice. Tat expression showed no significant effect. CNS sections from the striatum and spinal
cord stained for Iba-1+ cells (green) taken at × 20 with a higher magnification images taken at × 63. Scale bars = 50 μm. b Immunofluorescent images
were taken in the spinal cord at × 63 and show double-labeling for the microglial marker Iba-1 (green) and 3-nitrotyrosine (3-NT; red), a reactive
nitrosyl product detected in activated microglia, with containing Hoechst-stained nuclei. The 3-NT+ Iba1+ double-labeled microglia from a saline-
treated Tat(−) mouse is ramified and shows relative low level of 3-NT expression. In contrast the 3-NT+ Iba1+ double-labeled microglia from the
morphine-treated Tat(+) mouse shows decreased processes and the level of 3-NT is noticeably higher (see Table 2 for quantification via Sholl analysis).
Scale bars = 20 μm. Percent 3-NT+ Iba-1+ cell counts based on total number of Iba-1 cells was quantified in the striatum and spinal cord. Morphine
and Tat expression increased 3-NT+ Iba-1+ cell counts (%) in the striatum and spinal cord, specifically for morphine-treated Tat(+) mice. c Example of
a single microglial cell with concentric Sholl radii (purple circles) superimposed on the image. Scale bar = 20 μm. All data are expressed as mean ±
SEM. Statistical significance was assessed by ANOVA followed by Tukey’s post hoc test; *p < 0.05 main effect of drug; #p < 0.05 main effect of
genotype; §p < 0.05 vs. morphine-exposed Tat(+) mice. Morph short-term (8-day) morphine injections. n = 3–4 mice per group/4 sections each
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Cytokine production in the striatum and spinal cord
Protein levels of proinflammatory, anti-inflammatory,
and chemotactic cytokines were measured using a Bio-
Plex 23-plex multiplexed immunoassay within the stri-
atum and spinal cord tissue lysate (n = 5–6 per group;
Tables 3 and 4; Figs. 5 and 6). Cytokine levels for the
striatum and spinal cord were mixed but indicated
mostly higher levels in the spinal cord compared to the
striatum. A three-way mixed ANOVA with CNS region
as a within-subjects factor and genotype and drug as
between-subjects factors indicated a significant main ef-
fect of CNS region (p < 0.05) for all measured cytokines
except IL-13, with the spinal cord generally exhibiting
an increase in proinflammatory, anti-inflammatory, and
chemotactic cytokines. To assess Tat and morphine’s ef-
fect for each CNS region, separate two-way ANOVAs
for the striatum and spinal cord with genotype and drug
as between-subjects factors were conducted for each
cytokine, and are summarized in Figs. 5 and 6, with add-
itional cytokine measures being summarized in Tables 3
and 4.
Within proinflammatory cytokines (Tables 3 & 4, Fig.
5), Tat expression reduced striatal concentrations of IL-1α
[F(1, 19) = 5.3, p = 0.033] and IL-17A [F(1, 19) = 15.6, p =
0.001]. IL-3 protein levels were reduced in the spinal cord
of Tat (+) mice [F(1, 19) = 5.0, p = 0.038]. Morphine and
Tat treatments significantly interacted to reduce concen-
trations of inflammatory mediators IL-3 [F(1, 19) = 4.5, p
= 0.047] and IL-12p40 [F(1, 19) = 5.889, p = 0.025] within
the striatum. Morphine-treated, Tat(−) striatal samples
showed elevated IL-3 and IL-12p40 compared to saline-
treated, Tat(−) (IL-3, p = 0.028; IL-12p40, p = 0.025) and
Tat(+) (IL-3, p = 0.033; IL-12p40, p = 0.038), as well as
morphine-treated, Tat(+) mice (IL-3, p = 0.046; IL-12p40,
p = 0.024). In contrast, morphine exposure correlated with
increased protein concentrations of IL-1α [F(1, 19) =
Table 2 Effects of Tat and morphine on microglial morphology in the striatum and spinal cord of Tat transgenic mice
CNS region Measure Genotype Repeated saline Repeated morphine Genotype effect Drug effect Genotype
x drug
mean ± SEM mean ± SEM F1, 56 p F1, 56 p F1, 56 p
Striatum Soma area (μm2) Tat(−) 51.1 ± 2.16 46.7 ± 2.98 < 1.0 0.49 2.9 0.09 < 1.0 0.96
Tat(+) 49.2 ± 2.41 45.1 ± 2.00
Maximum branch length (μm) Tat(−) 35.3 ± 3.32 32.5 ± 2.59 < 1.0 0.59 < 1.0 0.84 1.7 0.20
Tat(+) 30.7 ± 1.90 34.4 ± 2.19
Critical radius (μm) Tat(−) 14.6 ± 1.56 13.4 ± 1.35 < 1.0 0.51 < 1.0 0.97 < 1.0 0.63
Tat(+) 14.4 ± 1.76 15.6 ± 1.20
Number of primary process Tat(−) 4.8 ± 0.56 4.1 ± 0.30 2.8 0.10 < 1.0 0.92 2.8 0.10
Tat(+) 3.5 ± 0.29 4.1 ± 0.45
Process maximum Tat(−) 6.8 ± 0.83 5.3 ± 0.60 < 1.0 0.93 < 1.0 0.70 2.3 0.13
Tat(+) 5.5 ± 1.00 6.4 ± 0.77
Process total Tat(−) 21.5 ± 3.02 16.1 ± 2.20 < 1.0 0.89 < 1.0 0.70 2.1 0.16
Tat(+) 16.9 ± 3.49 19.9 ± 2.77
Spinal cord Soma area (μm2) Tat(−) 48.5 ± 3.42 50.9 ± 3.79 4.2 0.04 3.8 0.06 1.5 0.23
Tat(+) 51.4 ± 2.45 62.2 ± 3.73
Maximum branch length (μm) Tat(−) 35.1 ± 2.59 36.2 ± 2.71 < 1.0 0.51 < 1.0 0.66 < 1.0 0.98
Tat(+) 33.4 ± 2.32 34.6 ± 2.19
Critical radius (μm) Tat(−) 16.7 ± 1.98 15.6 ± 1.20 < 1.0 0.44 < 1.0 0.98 < 1.0 0.61
Tat(+) 17.2 ± 2.28 18.1 ± 2.04
Number of primary process Tat(−) 2.3 ± 0.28 2.7 ± 0.33 < 1.0 0.81 1.5 0.23 5.0 0.03
Tat(+) 3.2 ± 0.47 2.0 ± 0.20
Process maximum Tat(−) 3.6 ± 0.31 4.6 ± 0.57 < 1.0 0.81 < 1.0 0.78 5.4 0.02
Tat(+) 4.8 ± 0.58 3.6 ± 0.27
Process total Tat(−) 11.5 ± 1.56 15.7 ± 2.30 < 1.0 0.58 < 1.0 0.95 5.1 0.03
Tat(+) 14.6 ± 1.75 10.6 ± 1.22
Sholl analysis of microglial morphology in the striatum and spinal cord of repeated (8-day) saline- or morphine-treated Tat(−) and Tat(+) mice. Data are expressed
as the mean ± SEM. The parameters measured by Sholl analysis are indicated in parentheses in the second column. One-way ANOVAs for each CNS region were
conducted with genotype and drug as between-subjects factors. F values and p values are presented from ANOVA results. Bolded values denote significant
differences at α = 0.05; mean ± SEM, n = 3–4 mice per group/4 sections each
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4.677, p = 0.044], IL-6 [F(1, 19) = 33.0, p < 0.001], IL-9
[F(1, 19) = 8.7, p = 0.008] and IL-12p70 [F(1, 19) = 4.7, p
= 0.043] within the striatum. Within the spinal cord, mor-
phine significantly reduced IL-1β [F(1, 19) = 5.9, p =
0.025], but increased concentrations of IL-2 [F(1, 19) =
16.9, p = 0.006], IL-9 [F(1, 19) = 13.0, p = 0.002], IL-12p70
[F(1, 19) = 15.1, p = 0.001], IL-17A [F(1, 19) = 4.748, p =
0.042], and IFN-γ [F(1, 19) = 6.2, p = 0.022].
Among anti-inflammatory cytokines (Tables 3 & 4,
Fig. 5), morphine increased the concentration of IL-5
[F(1, 19) = 26.0, p < 0.001] and IL-13 [F(1, 19) = 39.6, p
< 0.001] in the striatum, and IL-10 [F(1,19) = 7.4, p =
0.014] in the spinal cord, while Tat expression reduced
protein levels of IL-10 in the striatum [F(1, 19) = 12.0, p
= 0.003]. Morphine administration and Tat expression
significantly interacted to reduce IL-4 [striatum, F(1,19)
= 5.5, p = 0.030; spinal cord, F(1, 19) = 6.3, p = 0.022]
expression within the striatum and spinal cord. In the
striatum, morphine-treated Tat(+) mice had reduced IL-
4 compared to saline-treated Tat(−) mice (p = 0.047)
and morphine-treated Tat(−) mice (p = 0.008). In the
spinal cord, morphine-treated Tat(−) mice showed sig-
nificantly increased IL-4 compared to saline-treated con-
trols (Tat(−), p = 0.007; Tat(+), p = 0.023) and
morphine-treated, Tat(+) mice (p = 0.040).
Tat expression significantly reduced various chemokines
and colony-stimulating factors (Tables 3 & 4, Fig. 6), within
the striatum [G-CSF, F(1, 19) = 13.7, p = 0.002; GM-CSF,
F(1, 19) = 7.700, p = 0.012; CXCL1, F(1, 19) = 15.3, p <
0.001; CCL2, F(1, 19) = 13.6, p = 0.002; CCL4, F(1, 19) =
18.4, p < 0.001; CCL5, F(1, 19) = 10.20, p = 0.005] and
spinal cord [G-CSF, F(1, 19) = 6.1, p = 0.023; GM-CSF, F(1,
19 = 5.4, p = 0.032; CXCL1, F(1, 19) = 7.1, p = 0.015]. Mor-
phine treatment increased chemokine concentrations
within the spinal cord [G-CSF, F(1, 19) = 11.1, p = 0.004;
GM-CSF, F(1, 19) = 11.3, p = 0.003; CCL2, F(1, 19) = 12.7,
p = 0.002; CCL4, F(1, 19) = 20.3, p < 0.001; CCL5, F(1, 19)
= 4.9, p = 0.039]. Morphine treatment increased striatal
Table 3 Effects of Tat and morphine on cytokine concentrations in the striatum of Tat transgenic mice that are not presented in
Figs. 5 and 6
Striatal cytokines Genotype Repeated saline Repeated morphine Genotype effect drug effect Genotype x drug
pg/mL mean ± SEM mean ± SEM F1, 19 p F1, 19 p F1, 19 p
Proinflammatory Cytokines
IL-2 Tat(−) 10.7 ± 0.61 10.7 ± 0.18 < 1.0 0.59 < 1.0 0.48 < 1.0 0.50
Tat(+) 10.6 ± 0.33 11.2 ± 0.12
IL-6 Tat(−) 2.5 ± 0.08 3.2 ± 0.13 1.6 0.22 33.0 < 0.01 1.7 0.20
Tat(+) 2.5 ± 0.08 2.9 ± 0.13
IFN-γ Tat(−) 24.3 ± 0.63 24.9 ± 0.26 3.3 0.08 1.9 0.18 < 1.0 0.60
Tat(+) 22.6 ± 0.46 24.0 ± 1.40
TNF-α Tat(−) 45.1 ± 1.33 48.3 ± 1.58 < 1.0 0.87 2.9 0.11 < 1.0 0.68
Tat(+) 44.4 ± 1.47 49.9 ± 5.14
Anti-Inflammatory Cytokines
IL-5 Tat(−) 2.2 ± 0.15 2.8 ± 0.09 1.7 0.20 26.0 < 0.01 < 1.0 0.99
Tat(+) 2.0 ± 0.08 2.7 ± 0.20
IL-13 Tat(−) 36.9 ± 1.79 48.1 ± 0.99 3.4 0.08 39.6 < 0.01 < 1.0 0.54
Tat(+) 31.9 ± 0.93 45.7 ± 3.73
Chemokines
CCL2 Tat(−) 42.2 ± 1.36 42.3 ± 1.08 13.6 < 0.01 < 1.0 0.60 < 1.0 0.60
Tat(+) 38.4 ± 1.01 37.1 ± 1.38
CCL3 Tat(−) 8.3 ± 0.82 10.5 ± 1.08 < 1.0 0.66 3.2 0.09 < 1.0 0.45
Tat(+) 8.6 ± 0.63 9.5 ± 0.73
CCL4 Tat(−) 48.8 ± 0.42 47.8 ± 0.84 18.4 < 0.01 3.4 0.08 < 1.0 0.61
Tat(+) 46.0 ± 0.93 44.2 ± 0.70
CCL11 Tat(−) 99.9 ± 1.77 96.6 ± 1.24 2.2 0.15 1.3 0.27 < 1.0 0.85
Tat(+) 95.5 ± 3.53 91.0 ± 6.01
Cytokine concentrations in the striatum of repeated (8-day) saline- or morphine-treated Tat(−) and Tat(+) mice. Data are expressed as mean ± SEM in pg/mL.
Samples were loaded at 900 μg/mL total protein. Two-way ANOVAs for each CNS region were conducted with genotype and drug as between-subjects factors. F
values and p values are presented from ANOVA results. Bolded values denote significant differences at α = 0.05; n = 5–6 mice per group. Additional cytokines and
chemokines are represented in Figs. 5 and 6
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CCL5 [F(1, 19) = 10.2, p = 0.005]. No significant genotype
by drug interactions were observed in either region. Overall,
3-month Tat exposure increased innate immune tolerance
evidenced by reductions in specific cytokines (e.g., IL-1α,
IL-12p40), while short-term morphine exposure acted as a
secondary stressor revealing an allostatic shift in CNS base-
line inflammatory responsiveness from sustained Tat
exposure.
Levels of endocannabinoids and related non-eCB lipids in
the striatum and spinal cord
To assess the impact of chronic Tat and repeated mor-
phine exposure on the endogenous cannabinoid system,
changes in levels of endocannabinoids (eCBs) and other
lipid signaling molecules were assessed in the striatum
and spinal cord of Tat transgenic mice (n = 3–5 per
group; Table 5, Fig. 7). CNS region effects were noted;
2-AG [F(1, 13) = 4.7, p = 0.050] and AEA [F(1, 13) =
7.3, p = 0.018] levels were reduced in the spinal cord
compared to the striatum, whereas other lipids, includ-
ing NAGly [F(1, 13) = 14.4, p = 0.002], 2-LG [F(1, 13) =
9.6, p = 0.008], OEA [F(1, 13) = 5.2, p = 0.040], PEA
[F(1, 13) = 8.4, p = 0.013], DEA [F(1, 13) = 9.5, p =
0.009], and SEA [F(1, 13) = 7.9, p = 0.015], had higher
levels in the spinal cord compared to the striatum. To
assess Tat and morphine’s effect for each CNS region,
separate two-way ANOVAs for the striatum and spinal
cord were conducted with genotype and drug as
between-subjects factors. No effects were noted for AEA
and 2-AG on either of the two CNS structures and no
effects were noted for any of the other lipids on the
spinal cord (Table 5, Fig. 7b). For the striatum, no sig-
nificant changes on any of these measures were noted
for genotype, but morphine significantly upregulated
four of the other lipids, including 2-LG [F(1, 13) = 7.6, p
= 0.016], PEA [F(1, 13) = 7.4, p = 0.018], OEA [F(1, 13)
= 6.6, p = 0.023], and SEA [F(1, 13) = 8.9, p = 0.011]
(Fig. 7a). No differences were noted between individual
Table 4 Effects of Tat and morphine on cytokine concentrations in the spinal cord of Tat transgenic mice that are not presented in
Figs. 5 and 6
Spinal cord cytokines Genotype Repeated saline Repeated morphine Genotype effect Drug effect Genotype x drug
pg/mL mean ± SEM mean ± SEM F1, 19 p F1, 19 p F1, 19 p
Proinflammatory cytokines
IL-2 Tat(−) 12.5 ± 0.36 14.3 ± 0.47 2.3 0.15 16.9 < 0.01 < 1.0 0.98
Tat(+) 11.8 ± 0.44 13.6 ± 0.46
IL-6 Tat(−) 3.4 ± 0.17 3.6 ± 0.19 1.5 0.24 1.5 0.23 < 1.0 0.79
Tat(+) 3.2 ± 0.13 3.4 ± 0.19
IFN-γ Tat(−) 29.1 ± 0.76 30.3 ± 0.71 < 1.0 0.38 6.2 0.02 < 1.0 0.37
Tat(+) 27.8 ± 0.74 30.3 ± 0.76
TNF-α Tat(−) 52.4 ± 1.70 51.8 ± 1.67 1.6 0.22 1.6 0.22 2.8 0.11
Tat(+) 47.8 ± 1.73 52.4 ± 0.48
Anti-inflammatory cytokines
IL-5 Tat(−) 3.4 ± 0.22 3.4 ± 0.12 4.3 0.05 < 1.0 0.44 < 1.0 0.36
Tat(+) 3.2 ± 0.13 2.9 ± 0.11
IL-13 Tat(−) 40.8 ± 3.86 41.6 ± 3.27 1.6 0.21 1.7 0.20 2.4 0.14
Tat(+) 41.7 ± 2.73 32.4 ± 2.63
Chemokines
CCL2 Tat(−) 50.8 ± 1.13 57.7 ± 1.66 2.4 0.14 12.7 < 0.01 < 1.0 0.64
Tat(+) 48.9 ± 1.83 54.2 ± 2.24
CCL3 Tat(−) 5.1 ± 0.14 5.3 ± 0.19 3.5 0.08 < 1.0 0.71 < 1.0 0.53
Tat(+) 4.8 ± 0.21 4.8 ± 0.21
CCL4 Tat(−) 67.4 ± 1.27 74.5 ± 0.78 1.4 0.25 20.3 < 0.01 < 1.0 0.44
Tat(+) 66.9 ± 1.85 71.9 ± 1.18
CCL11 Tat(−) 108.4 ± 5.37 100.4 ± 4.32 < 1.0 0.57 < 1.0 0.72 1.7 0.20
Tat(+) 99.3 ± 4.37 103.9 ± 5.01
Cytokine concentrations in the spinal cord of repeated (8-day) saline- or morphine-treated Tat(−) and Tat(+) mice. Data are expressed as mean ± SEM in pg/mL.
Samples were loaded at 500 μg/mL total protein. Two-way ANOVAs for each CNS region were conducted with genotype and drug as between-subjects factors. F
values and p values are presented from ANOVA results. Bolded values denote significant differences at α = 0.05; n = 5–6 mice per group. Additional cytokines and
chemokines are represented in Figs. 5 and 6
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groups. Thus, even though eCB levels were unchanged
in either CNS structure, related non-eCB lipids, includ-
ing 2-LG, OEA, PEA, and SEA, significantly increased
with morphine exposure in the striatum but not in the
spinal cord, irrespective of Tat exposure.
Levels of amino acids in the striatum and spinal cord
As neuroinflammation, assessed by Iba-1+ cells
and 3-NT+ Iba-1+ double-labeled cells, was signifi-
cantly upregulated in morphine-exposed Tat(+) mice,
we determined the impact of chronic Tat and re-
peated morphine exposure on various amino acids in
the striatum and spinal cord (n = 3–5 per group;
Table 6, Fig. 8). Multiple amino acids including
glutamic acid [F(1, 13) = 165.76, p < 0.008], glycine
[F(1, 13) = 147.2, p < 0.001], phenylalanine [F(1, 13)
= 5.0, p = 0.043], proline [F(1, 13) = 19.2, p =
0.001], and serine [F(1, 13) = 84.7, p < 0.001] were
differentially expressed across CNS regions and indi-
cated higher levels in the striatum compared to the
spinal cord, except for glycine. To assess Tat and
morphine’s effect for each CNS region, separate two-
way ANOVAs for the striatum and spinal cord were
conducted with genotype and drug as between-
subjects factors. No effects were noted for arginine,
aspartic acid, glutamic acid, and glycine on any of
the two CNS structures (Table 6). For the striatum,
no significant changes on any of the other measures
Fig. 5 Cytokine concentrations (pg/mL) are impacted by Tat exposure and morphine in the striatum (a) and spinal cord (b) of Tat transgenic
mice. Proinflammatory cytokines showed morphine- and Tat-specific effects in the striatum and spinal cord. Morphine treatment led to a
significant increase in multiple proinflammatory cytokines in the striatum (IL-1α, IL-9, IL-12p70) and spinal cord (IL-9, IL-12p70, IL-17A), while
reducing IL-1β in the spinal cord. Tat exposure reduced several cytokines in the striatum (IL-1α, IL-17A) and spinal cord (IL-3). Morphine and
Tat interactions were noted for IL-3 and IL-12p40 in the striatum. Anti-inflammatory cytokine IL-10 (highlighted, bottom right) was elevated by
morphine in the spinal cord and reduced by Tat expression in the striatum, whereas IL-4 indicated a significant morphine by Tat interaction for
both CNS regions. All data are expressed as mean pg/mL ± SEM. Samples were normalized to 900 μg/mL (striatum) or 500 μg/mL (spinal cord)
via BCA. Statistical significance was assessed by ANOVA followed by Tukey’s post hoc test; *p < 0.05 main effect of drug; #p < 0.05 main effect of
genotype; †p < 0.05 vs. morphine-exposed Tat(−) mice; §p < 0.05 vs. morphine-exposed Tat(+) mice. Morph short-term (8-day) morphine
injections. n = 5–6 mice per group
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were noted for Tat expression, but morphine signifi-
cantly upregulated phenylalanine [F(1, 13) = 6.5, p =
0.024] and proline [F(1, 13) = 4.7, p = 0.050], and
significantly downregulated serine [F(1, 13) = 9.9, p
= 0.008] (Fig. 8a). No differences were noted be-
tween individual groups. For the spinal cord, Tat ex-
pression significantly upregulated leucine [F(1, 13) =
7.0, p = 0.020] and valine [F(1, 13) = 12.5, p =
0.004]. Further, morphine downregulated tyrosine
and valine [F(1, 13) = 5.5, p = 0.035 and F(1, 13) =
15.7, p = 0.002, respectively] (Fig. 8b). For valine,
saline-treated Tat(+) mice demonstrated increased
levels compared to morphine-treated Tat(−) mice (p
= 0.002) and morphine-treated Tat(+) mice (p =
0.041; Fig. 8b). Together, these data show that the
amino acids phenylalanine and proline were signifi-
cantly increased by repeated morphine exposure in
the striatum, whereas in the spinal cord, Tat expos-
ure increased amino acids leucine and valine, while
morphine decreased levels of tyrosine and valine.
Discussion
The present study investigated short-term (8-day) mor-
phine’s effects in the Tat transgenic mouse model on
antinociceptive tolerance, brain inflammatory processes,
and expression levels of eCB, related non-eCB lipids and
amino acids. Here, we report that Tat expression en-
hanced the magnitude of morphine tolerance specifically
for the tail-flick task with less robust changes in the
supraspinal-related hot-plate assay, potentially due to
the small sample size that increased the likelihood of
type II error. It also should be noted that the data for
the morphine-exposed Tat(+) mice are based on esti-
mated ED50 value and therefore caution needs to be
Fig. 6 Chemokine levels (pg/mL) are altered by Tat exposure or morphine in the striatum (a) and spinal cord (b) of Tat transgenic mice.
Concentrations of chemokines were assessed using a Bio-Plex cytokine array. G-CSF, GM-CSF, and CXCL1 showed significant Tat-induced
reductions in both regions, while CCL5 was only reduced in striatum (#p < 0.05). Morphine treatment increased G-CSF and GM-CSF
concentrations within the spinal cord, and CCL5 concentrations in both regions. All data are expressed as mean pg/mL ± SEM. Samples were
normalized to 900 μg/mL (striatum) or 500 μg/mL (spinal cord) via BCA. Statistical significance was assessed by ANOVA followed by Tukey’s post
hoc test; *p < 0.05 main effect of drug; #p < 0.05 main effect of genotype. Morph short-term (8-day) morphine injections. n = 5–6 mice per group
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exercised when interpreting the data. Additionally, Tat
expression and morphine exposure significantly de-
creased body mass, which has been demonstrated in pre-
vious studies [98, 101] and is a well-established effect of
administering high dose, acute morphine. Interestingly, a
sustained (3-month) Tat insult appeared to induce in-
nate immune tolerance because Tat exposure alone (1)
no longer significantly increased microglial reactivity, (2)
failed to increase the brain inflammatory marker [18F]-
PBR111 during PET imaging, and (3) reduced levels of
specific cytokines (e.g., IL-1α, IL-12p40), which are ele-
vated by shorter duration (28-day) Tat induction [54].
Furthermore, short-term, escalating morphine exposure
(designed to mimic accelerated abuse of opiates as seen
with prescription opiate abuse) revealed that prolonged
Tat exposure caused an allostatic shift in baseline in-
flammatory processes in the CNS. Moreover, whereas no
changes in eCB levels were noted in either of the two
CNS regions, other related non-eCB lipids, including 2-
LG, OEA, PEA, and SEA significantly increased with re-
peated short-term morphine exposure in the striatum
but not in the spinal cord, irrespective of Tat exposure.
Absolute levels of these lipids were greater in the spinal
cord than striatum, collectively suggesting fundamental
differences in lipid biosynthesis/degradation and respon-
siveness to opiates between the two regions.
Table 5 Effects of Tat and morphine on levels of eCB and other lipid signaling molecules (pg/mg) in the striatum and spinal cord of
Tat transgenic mice that were not significantly altered by Tat and/or morphine for any of the two CNS regions
CNS
region
Lipids Genotype Repeated saline Repeated morphine Genotype effect Drug effect Genotype x drug
pg/mg mean ± SEM mean ± SEM F1, 13 p F1, 13 p F1, 13 p
Striatum 2-AG Tat(−) 11879.7 ± 1270.52 15441.7 ± 2440.16 < 1.0 0.93 2.1 0.17 < 1.0 0.52
Tat(+) 13140.9 ± 2086.96 14476.7 ± 1229.29
AEA Tat(−) 8.4 ± 0.52 9.1 ± 1.87 2.3 0.15 < 1.0 0.47 2.3 0.15
Tat(+) 8.4 ± 1.08 6.4 ± 0.33
NAGly Tat(−) 16.0 ± 1.18 17.0 ± 1.26 < 1.0 0.47 1.0 0.33 < 1.0 0.85
Tat(+) 16.7 ± 1.55 18.10 ± 0.62
POEA Tat(−) 4.9 ± 0.34 5.9 ± 0.93 1.1 0.31 < 1.0 0.36 1.5 0.24
Tat(+) 5.0 ± 0.23 4.8 ± 0.39
LEA Tat(−) 6.0 ± 0.74 7.9 ± 1.71 < 1.0 0.46 < 1.0 0.96 3.2 0.10
Tat(+) 7.1 ± 1.33 5.2 ± 0.67
DEA Tat(−) 2.8 ± 0.09 3.6 ± 0.91 < 1.0 0.39 1.1 0.32 1.7 0.22
Tat(+) 2.9 ± 0.20 2.8 ± 0.16
DHEa Tat(−) 16.1 ± 0.64 18.1 ± 4.25 < 1.0 0.66 < 1.0 0.58 2.9 0.11
Tat(+) 18.4 ± 1.99 14.3 ± 0.61
Spinal cord 2-AG Tat(−) 11168.1 ± 1849.25 13770.4 ± 4148.01 1.4 0.26 1.4 0.26 < 1.0 0.90
Tat(+) 9033.6 ± 993.83 11126.1 ± 1239.95
AEA Tat(−) 5.8 ± 0.79 5.7 ± 2.03 < 1.0 0.77 < 1.0 0.60 < 1.0 0.55
Tat(+) 5.3 ± 0.48 7.1 ± 1.98
NAGly Tat(−) 22.8 ± 2.07 22.3 ± 4.38 < 1.0 0.43 < 1.0 0.74 < 1.0 0.56
Tat(+) 19.6 ± 1.81 21.7 ± 1.19
POEA Tat(−) 8.7 ± 3.12 4.9 ± 0.58 < 1.0 0.83 < 1.0 0.71 < 1.0 0.38
Tat(+) 6.7 ± 2.02 8.3 ± 3.38
LEA Tat(−) 10.6 ± 4.75 5.7 ± 1.40 < 1.0 0.66 < 1.0 0.78 < 1.0 0.52
Tat(+) 9.5 ± 3.85 11.4 ± 6.26
DEA Tat(−) 3.9 ± 0.30 3.8 ± 1.19 < 1.0 0.82 < 1.0 0.37 1.1 0.32
Tat(+) 3.2 ± 0.42 4.3 ± 0.57
DHEa Tat(−) 15.8 ± 0.55 18.4 ± 6.49 < 1.0 0.61 1.5 0.24 < 1.0 0.48
Tat(+) 14.7 ± 1.02 24.9 ± 7.59
Levels of eCB and non-eCB lipids in the striatum and spinal cord of repeated (8-day) saline- or morphine-treated Tat(−) and Tat(+) mice were not significantly
affected by Tat and/or morphine for any of the two CNS regions. Data are expressed as mean ± SEM in pg/mg. Two-way ANOVAs for each CNS region were
conducted with genotype and drug as between-subjects factors. F values and p values are presented from ANOVA results. n = 3–5 mice per group. All significant
effects are represented in Fig. 7
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Amino acids
Besides a suggested role of glial activation in morphine-
induced antinociceptive tolerance, Tat exposure induced
specific alterations in various amino acids in a CNS
region-dependent manner. Tat elicited an upregulation
of the branched-chain (having an aliphatic side chain)
amino acids (BCAAs) leucine and valine in the spinal
cord (isoleucine as the third BCAA was not assessed in
this study), which participate directly and indirectly in
intermediary metabolism, protein synthesis, and in
neuropeptide neurotransmitters biosynthesis [102–104].
Whereas anti-inflammatory activities have been related
to BCAAs [74, 105], high brain concentrations of BCAA
may have detrimental effects on protein synthesis,
neurotransmitter synthesis and release, and promote
oxidative stress and inflammation [76, 106]. As inflam-
mation and oxidative stress have been demonstrated
after Tat exposure in vivo and in vitro [34, 37, 38, 54,
107–109], understanding the role of BCAAs in Tat tox-
icity requires more detailed investigation.
Short-term morphine exposure significantly changed
levels of the aromatic amino acids (i.e., having an aro-
matic side chain) phenylalanine and tyrosine in a CNS
region-dependent manner. These findings are interesting
considering the essential role of phenylalanine and its
conversion to tyrosine in catecholamine synthesis [110]
and bearing in mind the wide-spread alterations in cate-
cholamines (i.e., dopamine, norepinephrine, and epi-
nephrine) in neuroHIV [111]. Specifically, it has been
shown that immune activation can lead to diminished
conversion of phenylalanine to tyrosine as evidenced by
a higher phenylalanine/tyrosine (P/T) ratio [112], which has
been shown to be present in HIV-infected patients [113]
and potentially contributes to the dopamine deficiency in
people living with HIV [114]. The downregulation of tyro-
sine in the spinal cord (but not striatum) following repeated
morphine treatment supports findings in brain tissue of
mice chronically exposed to heroin [60] and has been
shown to allay some of the effects of opioid withdrawal
[73]. In turn, we also report here that morphine leads to a
Fig. 7 Morphine treatment increased 2-LG, OEA, PEA, and SEA concentrations (pg/mg) in the striatum but not spinal cord of Tat transgenic mice.
Concentrations of 2-AG and AEA and other lipid molecules were assessed in the striatum and spinal cord on saline and morphine-treated Tat
transgenic mice using LC/MS/MS. Lipid concentrations were normalized to pg/mg of tissue. a In the striatum, morphine significantly upregulated
2-LG, OEA, PEA, and SEA concentrations in Tat(+) and Tat(−) mice. b In the spinal cord, no significant effects were noted on any of the 4
measures. All data are expressed as mean ± SEM. Statistical significance was assessed by ANOVA followed by Tukey’s post hoc test; *p < 0.05
main effect of drug. Morph short-term (8-day) morphine injections. n = 3–5 mice per group
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Table 6 Effects of Tat and morphine on amino acid levels (pg/mg) in the striatum and spinal cord of Tat transgenic mice that were
not significantly altered by Tat and/or morphine for any of the two CNS regions
CNS Region Lipids Geno-type Repeated Saline Repeated Morphine Genotype Effect Drug Effect Genotype x Drug
pg/mg mean ± SEM mean ± SEM F1, 13 p F1, 13 p F1, 13 p
Striatum Arginine Tat(−) 68.5 ± 4.98 78.5 ± 8.12 < 1.0 0.81 3.3 0.09 < 1.0 0.81
Tat(+) 68.5 ± 4.26 76.1 ± 2.85
Aspartic Acid Tat(−) 2937.1 ± 147.50 2943.6 ± 323.69 < 1.0 0.83 < 1.0 0.80 < 1.0 0.78
Tat(+) 3049.2 ± 240.15 2927.9 ± 207.52
Glutamic Acid Tat(−) 9774.8 ± 373.58 9707.57 ± 964.41 < 1.0 0.80 < 1.0 0.66 < 1.0 0.58
Tat(+) 9605.3 ± 737.84 10,171.0 ± 259.75
Glycine Tat(−) 1276.5 ± 120.56 1375.7 ± 150.47 < 1.0 0.59 < 1.0 0.63 < 1.0 0.79
Tat(+) 1240.2 ± 162.27 1269.0 ± 81.91
Spinal Cord Arginine Tat(−) 60.4 ± 4.37 66.7 ± 16.23 1.5 0.24 2.9 0.11 < 1.0 0.40
Tat(+) 63.1 ± 1.99 82.3 ± 6.92
Aspartic Acid Tat(−) 3237.1 ± 134.52 3031.0 ± 742.06 < 1.0 0.64 < 1.0 0.90 < 1.0 0.47
Tat(+) 3148.3 ± 241.28 3442.9 ± 293.20
Glutamic Acid Tat(−) 6286.3 ± 403.32 5867.4 ± 1186.47 < 1.0 0.99 < 1.0 0.65 < 1.0 0.77
Tat(+) 6128.7 ± 252.56 6031.6 ± 418.03
Glycine Tat(−) 4221.2 ± 165.88 3868.8 ± 780.64 < 1.0 0.97 < 1.0 0.63 1.8 0.20
Tat(+) 3647.5 ± 367.56 4414.7 ± 405.38
Levels of amino acids in the striatum and spinal cord of repeated (8-day) saline- or morphine-treated Tat(−) and Tat(+) mice were not significantly affected by Tat
and/or morphine for any of the two CNS regions. Data are expressed as mean ± SEM in pg/mg. Two-way ANOVAs for each CNS region were conducted with
genotype and drug as between-subjects factors. F values and p values are presented from ANOVA results. n = 3–5 mice per group. All significant effects are
represented in Fig. 8
Fig. 8 Amino acid levels (pmol/mg) are significantly altered by Tat exposure or morphine depending on the CNS region assessed. The concentrations
of various amino acids were assessed in the striatum and spinal cord on saline and morphine-treated Tat transgenic mice using hydrophilic interaction
chromatography (HILIC)-LC/MS/MS. Amino acid concentrations were normalized to pmol/mg of tissue. a In the striatum, morphine significantly
upregulated phenylalanine and proline concentrations, and significantly downregulated serine levels in Tat(+) and Tat(−) mice. b In the spinal cord, Tat
expression increased leucine and valine levels, whereas morphine significantly decreased valine and tyrosine levels. All data are expressed as mean ±
SEM. Statistical significance was assessed by ANOVA followed by Tukey’s post hoc test; *p < 0.05 main effect of drug; #p < 0.05 main effect of
genotype; §p < 0.05 vs. saline-exposed Tat(+) mice. Morph short-term (8-day) morphine injections. n = 3–5 mice per group
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significant upregulation of phenylalanine in the striatum
(but not spinal cord) of Tat(−) mice. Similarly, rats self-
administrating heroin [59] and mice undergoing heroin
withdrawal [60] showed elevated levels of phenylalanine in
serum. The lack of elevated phenylalanine concentrations
in the spinal cord suggests regional differences in its metab-
olism (similar to tyrosine), which may coincide with re-
gional differences in morphine concentration in the CNS
[40]. Interestingly, Tat induction appeared to negate
morphine-dependent increases in striatal phenylalanine in
our study and Tat and/or HIV exposure have been associ-
ated with pathophysiological alterations in dopamine [115–
118].
Lastly, proline and phenylalanine have been reported
to display anti-inflammatory effects [74, 119] and were
significantly upregulated in the striatum by short-term,
escalating morphine exposure. The anti-inflammatory
effects of morphine have not been clearly demonstrated
but various recent studies point toward that direction
[54, 120]. Additionally, in the present study, we show
that morphine administration significantly downregu-
lates the amino acid serine in the striatum. Though ser-
ine’s effects on the CNS are currently debated [121–
123], the downregulation of serine by morphine point
again to a morphine-induced anti-inflammatory effect
[121], which is also supported by our findings of
morphine-induced increases in the anti-inflammatory
cytokines IL-4 and IL-10 in the spinal cord.
Endocannabinoids
The upregulation of anti-inflammatory amino acids by
short-term morphine exposure in the striatum could be
potentially explained by the changes observed on eCBs
and related non-eCB lipid signaling molecules. Even
though no effects were noted for AEA and 2-AG, mor-
phine exposure significantly upregulated other lipids in
the striatum, which are structurally related to AEA
(PEA, OEA, SEA) and 2-AG (2-LG), but do not activate
cannabinoid receptors. PEA and OEA activate other G-
protein-coupled receptors, including GPR55 and
GPR119 [124, 125], and other receptor systems includ-
ing peroxisome proliferator-activated alpha receptors
(PPAR-α [126, 127];), and/or transient receptor potential
vanilloid 1 (TRPV1) channels [128–130]. Notably, PEA,
OEA, and SEA share the same hydrolytic enzyme as
AEA, fatty acid amide hydrolase (FAAH). The average
concentrations of the lipids are approximately or above
100 pmol/g tissue, whereas AEA is found at much lower
levels of 1–30 pmol/g [131, 132]. When discussing the
biological roles of PEA, OEA, and SEA, it can often be
difficult to differentiate involvement of these lipids with
those of AEA since their levels in the tissues are often
altered in parallel with changes in AEA [133–136]. How-
ever, some studies indicate that PEA, OEA, and/or SEA
may have individual non-cannabinoid roles, e.g., OEA
and PEA exert anti-inflammatory and antioxidant neuro-
protection via activation of PPAR-α [126, 137–139]. The
targets for SEA are less clear, even though it is known
that it lacks affinity for the CB1R, but it does have some
cannabimimetic actions in rats in vivo [140]. Further,
PPARs can reduce the development of morphine toler-
ance by activating PPAR-γ [65]. We speculate that the
morphine-dependent increases in production of PEA,
OEA, SEA, and 2-LG, as well as the upsurges in anti-
inflammatory (phenylalanine and proline) and decreases
in proinflammatory (serine) amino acids, represent a
homeostatic response to the rapid increases in neuroin-
flammation seen with acute morphine exposure in the
presence of an inflammatory insult such as Tat. The ac-
tivation of selective PPARs, TRPV1, GPR55, and/or
GPR119 by these endogenous ligands may be important
in breaking the cycle and return to steady state, and one
or more of these receptors may be important therapeutic
targets for opiate abuse and HIV-1 comorbidity or for
the management of pain.
Neuroinflammation
Several studies demonstrate increased gliosis, macro-
phage turnover, and encephalitis in HIV-1 infected
humans who abuse opiates [10–12], which also has been
supported in various mouse models of neuroHIV-opiate
co-exposure [141–143]. In the current study, combined
Tat and morphine together induced significant increases
in the number of microglia and the proportion display-
ing nitrosative products in the striatum and spinal cord,
which were not evident with Tat alone. Additionally, ab-
normal microglial morphology was assessed in the spinal
cord upon Tat and morphine exposure. By contrast, in-
creases in TSPO levels via PET imaging were not dem-
onstrated through the [18F]-PRB111 ligand. The
discrepancy between the TSPO and Iba-1 results could
be that the [18F]-PRB111 ligand lacks sufficient sensitiv-
ity to detect small changes in TSPO levels or subtle
changes in neuroinflammation. Although increased
[18F]-PRB111 uptake has been demonstrated in several
animal models of neurological diseases including epi-
lepsy [144, 145], multiple sclerosis [146], and schizo-
phrenia [147], these models display extensive
inflammation and postmortem pathology [144–147],
whereas abnormalities in the HIV-1 Tat transgenic
mouse model are more subtle [148] with opioid expos-
ure inducing modest gliosis [29, 149]. Alternatively, in-
creases in TSPO may be most dramatic in
proinflammatory “M1” microglia when initially activated
and may decline with sustained activation or upon
switching to a repair/remodeling “M2” phenotype [150–
152]—although there is clearly a spectrum of functional
states beyond binary M1/M2 polarization [153]. With
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sustained Tat exposure, we speculate that microglia shift
toward a less proinflammatory, M2-like phenotype and
that innate immune responsiveness in the CNS becomes
increasingly tolerant to Tat. In fact, this assertion is sup-
ported by the reductions seen in key regulatory cyto-
kines and chemokines, increases in anti-inflammatory
cytokines (discussed below), and the absence of Tat-
dependent increases in microglial numbers and/or acti-
vation as assessed by immunohistochemistry and PET
imaging.
A previous study has demonstrated increased binding
of the related TPSO PET imaging [11C]N,N-diethyl-2-[2-
(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimi-
din-3-yl]acetamide ([11C]-DPA-713) ligand in the brains
of HIV-1 infected patients [154]. Although the reason
for the disparity is uncertain, unlike Tat in which ex-
pression levels are designed to remain constant with
continuous DOX treatment, neuroHIV can persist as a
dynamic, smoldering infection (albeit at low levels) des-
pite cART and may be more likely to promote a proin-
flammatory phenotype than constant Tat exposure.
Although the TSPO PET imaging and Iba-1 estimates of
microglial density/reactivity were in general agreement
following sustained Tat exposure, the measures did not
agree with combined morphine and Tat exposure. While
the reason(s) for the disparity is (are) uncertain, short-
term morphine exposure may revert “M2” microglia to-
ward an “M1” proinflammatory phenotype as evidenced
by increases in some proinflammatory cytokines only seen
with Tat and morphine co-exposure (discussed below).
Alternatively, the discrepancy between the TSPO PET im-
aging and Iba-1 findings may also relate to the selectivity
of [18F]-PRB111 as a microglial marker. While Iba-1 is se-
lective for microglia and macrophages, the specific glial
type(s) upregulating TPSO during inflammation [155] re-
main(s) a point of discussion as TPSO activation has been
demonstrated in astrocytes [156–158].
Repeated inflammatory insults can induce long-term
innate immune tolerance within resident microglia in
the CNS [159–161]. A recent study demonstrated that a
single intraperitoneal (i.p.) injection of lipopolysacchar-
ide (LPS) potentiated microglial inflammatory activity in
response to a secondary insult (transgenic amyloid pre-
cursor protein expression) 6 months later, whereas re-
peated i.p. doses of LPS dampened IL-6 production, with
similar trends in IL-1β, IL-10 and CXCL1 [57], thus in-
dicating longer-term immune tolerance akin to the im-
munosuppression [55–57]. Multiple LPS injections also
dampened acute IL-1β production in a brain ischemia
model, which correlated to reduced microglial activation
and improved neuronal survival [57]. Reduced microglial
IL-1β production was observed up to 32 weeks after
mice were primed with a peripheral LPS injection [160].
In several of these studies, innate immune tolerance
involved epigenetic reprogramming dependent on his-
tone deacetylasese-1 and -2 as well as TAK1-dependent
NF-κB signaling [57, 160], though additional mecha-
nisms are likely to be operative.
Sustained (3-month) Tat exposure not only failed to
increase but actually reduced levels of many cytokines
and chemokines. This included G-CSF, GM-CSF, IL-5,
and CXCL1 in the spinal cord, and notably IL-1α, IL-
17A, IL-10, G-CSF, GM-CSF, CXCL1, CCL2, CCL4, and
CCL5 in the striatum, which differs from the cytokine
increases seen with ≤ 1-month Tat exposure durations
[38, 54]. Microgliosis was also not evident in the stri-
atum or spinal cord, despite being present in the stri-
atum following 48 h [29] or 12 days [31] exposure to
Tat alone. We speculate that the inflammatory contribu-
tions of microglia per se differ in each region and situ-
ation, and underlie unique differences in the profile of
inflammatory factors (including cytokines and lipid me-
diators) that drive regional and temporal differences in
the pathology. Single-cell RNA-sequencing and related
strategies would be advantageous in confirming the role
of microglial heterogeneity as underlying spatiotemporal
differences in opioid-HIV comorbid pathobiology. Col-
lectively, our findings suggest that, despite some differ-
ences in the profile of cytokine changes between the
striatum and spinal cord, the innate immune response
had become tolerant to Tat. Moreover, the normally co-
ordinated production of pro- and anti-inflammatory cy-
tokines also became unbalanced, indicating that Tat-
induced innate immune tolerance in the CNS is accom-
panied by immune dysregulation, which is emblematic
in HIV-infected individuals [162] and frequently seen in
neuroHIV [163–165].
Conclusions
In the present study, we evaluated the impact of a short-
term ramping morphine regimen sufficient to cause opi-
ate tolerance to mimic the escalating consumption seen
with prescription opiate abuse in mutant mouse model
displaying chronic elevations of Tat (Fig. 2). Although
2–14 days of morphine and Tat/HIV co-exposure typic-
ally exacerbates cytokine production, gliosis, and by-
stander neuronal injury in vitro [30, 37, 43, 166] and
in vivo [29, 38], 3 months of Tat induction elicited a far
less fulminant morphine-dependent interactive path-
ology. Morphine and Tat co-exposure elevated 3-NT in
microglia, but failed to increase microglial numbers as
seen previously following 48 h or 12-day Tat induction
[29, 31]. Importantly, the final 80 mg/kg s.c. morphine
dose used in prior studies delivers approximately the
same amount of morphine during 24 h as a 25 mg time-
release pelleted implant (NIDA Drug Supply System)
[29, 35, 38]. Thus, the Tat-induced reductions in certain
cytokines (e.g., IL-1α, IL-17A) suggests that adaptive
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responses of some cytokines to Tat are more coordi-
nated across some brain regions than others. Import-
antly, by delaying exposure until these adaptative
processes had occurred, the response to morphine dif-
fered markedly from that previously seen with a shorter
duration of Tat exposure. Accordingly, altering the tim-
ing of morphine co-exposure revealed an allostatic shift
in CNS baseline cytokine responsiveness resulting from
sustained Tat exposure. The manner by which duration
of HIV infection might differentially interact with opiate
exposure to affect other outcome measures, especially
neuronal injury and dysfunction, remains uncertain but
is a compelling area for further investigation. In sum,
our results suggest that the nature and timing of opiate
and HIV comorbid interactions have dramatically differ-
ent consequences for addictive behavior and neuroHIV
pathogenesis.
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